According to Huisheng Biotech's announcement, the controlling shareholder of the company, Wuhan Tongsheng Investment Co., Ltd. holds 82.8 million shares of the company, accounting for 41.03% of the company's total share capital. It plans to transfer no more than 4 million shares of the company to Yu Jiaoe, one of the actual controllers of the company, within three months after 15 trading days from the date of disclosure of the announcement, accounting for 1.98% of the company's total share capital. This share transfer is an internal transfer between the controlling shareholder and actual controller. The total shareholding ratio and quantity have not changed, and will not lead to a change in the company's control, nor will it have a significant impact on the company's governance structure and continuous operation.

According to Huisheng Biotech's announcement, the controlling shareholder of the company, Wuhan Tongsheng Investment Co., Ltd. holds 82.8 million shares of the company, accounting for 41.03% of the company's total share capital. It plans to transfer no more than 4 million shares of the company to Yu Jiaoe, one of the actual controllers of the company, within three months after 15 trading days from the date of disclosure of the announcement, accounting for 1.98% of the company's total share capital. This share transfer is an internal transfer between the controlling shareholder and actual controller. The total shareholding ratio and quantity have not changed, and will not lead to a change in the company's control, nor will it have a significant impact on the company's governance structure and continuous operation.